logo-loader
viewReNeuron Group PLC

ReNeuron's retinal treatment 'appears to have sustained long-term beneficial effect'

ReNeuron Group PLC's (LON:RENE) Michael Hunt caught up with Proactive London's Andrew Scott soon after the firm announced that its cell therapy for a degenerative eye disease held onto sight improvements for as long as a year after treatment.

The 12-month data reveal that people receiving surgery and the ReNeuron therapy could read seven more letters on a standard eye chart than those receiving surgery alone.

Quick facts: ReNeuron Group PLC

Price: 173 GBX

LSE:RENE
Market: LSE
Market Cap: £55.07 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ReNeuron signs retinal stem cell exclusivity agreement

ReNeuron Group Plc (LON:RENE) has inked a deal worth up to US$5mln ahead of potentially licensing out its ground-breaking its hRPC retinal stem cell technology and therapeutic programmes. CFO Michael Hunt says they're hoping the exclusivity agreement with an unnamed US-based speciality...

on 11/7/18

2 min read